Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diels

Showing results (311-320 of 351) with videos related to

Pageof 36
Sort By:
Journal of Clinical Microbiology|March 3, 2025
Direct thin-layer agar for bedaquiline-susceptibility testing of <i>Mycobacterium tuberculosis</i> at BSL2 level yields high accuracy in 15 days from sputum processingI Cuella-Martin, D Runyambo, S De Bock, et al.
Annals of Hematology|November 21, 2019
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemiaGilles Salles, Emmanuel Bachy, Lukas Smolej, et al.
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Current Medical Research and Opinion|November 28, 2017
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patientsTomáš Jelínek, Vladimír Maisnar, Luděk Pour, et al.
Antiviral Research|December 29, 2023
A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effectsJordi Doijen, Inha Heo, Koen Temmerman, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Plastic and Reconstructive Surgery|January 26, 2017
Worldwide Testing of the eFACE Facial Nerve Clinician-Graded ScaleCaroline A Banks, Nathan Jowett, Babak Azizzadeh, et al.
Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.
Tuberculosis (Edinburgh, Scotland)|April 30, 2017
Significant under expression of the DosR regulon in M. tuberculosis complex lineage 6 in sputumBoatema Ofori-Anyinam, Gregory Dolganov, Tran Van, et al.
Pageof 36

Showing results (311-320 of 351) with videos related to

Sort By:
Pageof 36
Journal of Clinical Microbiology|March 3, 2025
Direct thin-layer agar for bedaquiline-susceptibility testing of <i>Mycobacterium tuberculosis</i> at BSL2 level yields high accuracy in 15 days from sputum processingI Cuella-Martin, D Runyambo, S De Bock, et al.
Annals of Hematology|November 21, 2019
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemiaGilles Salles, Emmanuel Bachy, Lukas Smolej, et al.
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Current Medical Research and Opinion|November 28, 2017
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patientsTomáš Jelínek, Vladimír Maisnar, Luděk Pour, et al.
Antiviral Research|December 29, 2023
A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effectsJordi Doijen, Inha Heo, Koen Temmerman, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Plastic and Reconstructive Surgery|January 26, 2017
Worldwide Testing of the eFACE Facial Nerve Clinician-Graded ScaleCaroline A Banks, Nathan Jowett, Babak Azizzadeh, et al.
Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.
Tuberculosis (Edinburgh, Scotland)|April 30, 2017
Significant under expression of the DosR regulon in M. tuberculosis complex lineage 6 in sputumBoatema Ofori-Anyinam, Gregory Dolganov, Tran Van, et al.
Pageof 36